Novel boron-containing, nonclassical antifolates: Synthesis and preliminary biological and structural evaluation

Journal of Medicinal Chemistry

Volumn 50, Issue 14, 2007, Pages 3283-3289

  Reynolds, Robert C ^a   Campbell, Shiela R ^a   Fairchild, Ralph G ^b   Kisliuk, Roy L ^c   Micca, Peggy L ^b   Queener, Sherry F ^d   Riordan, James M ^a   Sedwick, W David ^e   Waud, William R ^a   Leung, Adelaine K W ^a,h   Dixon, Richard W ^f   Suling, William J ^a   Borhani, David W ^a,f,g  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

^b BROOKHAVEN NATIONAL LABORATORY   (United States)

^c TUFTS UNIVERSITY   (United States)

^d INDIANA UNIVERSITY   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f ABBOTT LABORATORIES   (United States)

^g D E SHAW RESEARCH   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIAMINO 6 METHYLPYRIDINE; 5 (1,2 CLOSO DICARBADODECABORAN 1 YL)METHYLPYRIMIDINE; 5 (7,8 NIDO DICARBAUNDECARBORAN 7 YL)METHYLPYRIMIDINE; BORON DERIVATIVE; CARBORANE DERIVATIVE; DIHYDROFOLATE REDUCTASE; DIHYDRONICONATINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; ETHAMBUTOL; FOLIC ACID ANTAGONIST; METHOTREXATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TRIMETHOPRIM; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BLOOD; BRAIN; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVE SITE; GROWTH INHIBITION; HUMAN; HUMAN CELL; LACTOBACILLUS CASEI; LIPOPHILICITY; LIVER; LUNG; MELANOMA; MELANOMA CELL; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM AVIUM; NEUTRON CAPTURE THERAPY; NONHUMAN; PNEUMOCYSTIS CARINII; RAT; TISSUE DISTRIBUTION; TOXOPLASMA GONDII; TUMOR CELL; TUMOR CELL LINE; X RAY DIFFRACTION;

ANIMALS; BORON; BORON NEUTRON CAPTURE THERAPY; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; FOLIC ACID ANTAGONISTS; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; RATS; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 34447520293     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0701977     Document Type: Article

References (39)

1. Costi, M. P.; Ferrari, S. Update on antifolate drugs targets. Curr. Drug Targets 2001, 2, 135-166.
2. Takimoto, C. H.; Allegra, C. J. New antifolates in clinical development. Oncology 1995, 9, 649-656, 659 DISC 660, 662, 665.
3. Takemura, Y.; Kobayashi, H.; Miyachi, H. Antifolate resistance and its circumvention by new analogues. Hum. Cell 2001, 14, 185-202.
4. Calvert, H.; Bunn, P. A., Jr. Future directions in the development of pemetrexed. Semin. Oncol. 2002, 29, 54-61.
5. Periti, P. Brodimoprim, a new bacterial dihydrofolate reductase inhibitor: A minireview. J. Chemother. 1995, 7, 221-223.
6. Warhurst, D. C. Resistance to antifolates in Plasmodium falciparum, the causative agent of tropical malaria. Sci. Prog. 2002, 85, 89-111.
7. Sato, E. I. Methotrexate therapy in systemic lupus erythematosus. Lupus 2001, 10, 162-164.
8. Walker, V. K.; Tyshenko, M. G.; Kuiper, M. J.; Dargar, R. V.; Yuhas, D. A.; Cruickshank, P. A.; Chaguturu, R. Tobacco budworm dihydrofolate reductase is a promising target for insecticide discovery. Eur. J. Biochem. 2000, 267, 394-403.
9. Reynolds, R. C.; Johnson, C. A.; Piper, J. R.; Sirotnak, F. M. Synthesis and antifolate evaluation of the aminopterin analogue with a bicyclo[2.2.2]octane ring in place of the benzene ring. Eur. J. Med. Chem. 2001, 36, 237-242.
10. Grimes, R. N. Carboranes; Academic Press: New York, 1970.
11. Hitchings, G. H.; Baccanari, D. P. Design and synthesis of folate antagonists as antimicrobial agents. In Folate Antagonists as Therapeutic Agents. Volume I, Biochemistry, Molecular Actions and Synthetic Design; Sirotnak, F. M., Burchall, J. J., Ensminger, W. B., Montgomery, J. A., Eds.; Academic Press: New York, 1984; pp 151-172.
12. Barth, R. F.; Soloway, A. H.; Goodman, J. H.; Gahbauer, R. A.; Gupta, N.; Blue, T. E.; Yang, W.; Tjarks, W. Boron neutron capture therapy of brain tumors: An emerging therapeutic modality. Neurosurgery 1999, 44, 433-451; discussion 450-451, review.
13. Hawthorne, M. F. New horizons for therapy based on the boron neutron capture reaction. Mol. Med. Today 1998, 4, 174-181.
14. Gahbauer, R.; Gupta, N.; Blue, T.; Goodman, J.; Barth, R.; Grecula, J.; Soloway, A. H.; Sauerwein, W.; Wambersie, A. Boron neutron capture therapy: Principles and potential. Recent Res. Cancer Res. 1998, 150, 183-209.
15. Barth, R. F.; Yang, W.; Adams, D. M.; Rotara, J. H.; Shukla, S.; Sekido, M.; Tjarks, W.; Fenstermaker, R. A.; Ciesielski, M.; Nawrocky, M. M.; Coderre, J. A. Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomas. Cancer Res. 2002, 62, 3159-3166.
16. Reynolds, R. C.; Trask, T. W.; Sedwick, W. D. 2,4-Dichloro-5-(1-o- carboranylmethyl)-6-methylpyrimidine: A potential synthon for 5-(1-o-carboranylmethyl)pyrimidines. J. Org. Chem. 1991, 56, 2391-2395.
17. Wiesboeck, R. A.; Hawthorne, M. F. Dicarbaundecaborane(13) and derivatives. J. Am. Chem. Soc. 1964, 86, 1642-1643.
18. Maiti, S. N.; Singh, M. P.; Micetich, R. G. Facile conversion of azides to amines. Tetrahedron Lett. 1986, 27, 1423-1424.
19. Imamura, K.-i.; Yamamoto, Y. Synthesis and in vitro evaluation of 5-closo- and 5-nido-orthocarboranyluridines as boron carriers. Bull. Chem. Soc. Jpn. 1997, 70, 3103-3110.
20. Klon, A. E.; Heroux, A.; Ross, L. J.; Pathak, V.; Johnson, C. A.; Piper, J. R.; Borhani, D. W. Atomic structures of human dihydrofolate reductase complexed with NADPH and two lipophilic antifolates at 1.09 Å and 1.05 Å resolution. J. Mol. Biol. 2002, 320, 677-693.
21. Chandrasekhar, J.; Andrade, J. G.; Schleyer, P. v. R. Efficient and accurate calculation of anion proton affinities. J. Am. Chem. Soc. 1981, 103, 5609-5612.
22. Spitznagel, G. W.; Clark, T.; Chandrasekhar, J.; Schleyer, P. v. R. Stabilization of methyl anions by first-row substituents. The superiority of diffuse function-augmented basis sets for anion calculations. J. Comput. Chem. 1982, 3, 363-371.
23. Clark, T.; Chandrasekhar, J.; Spitznagel, G. W.; Schleyer, P. v. R. Efficient diffuse function-augmented basis sets for anion calculations. III. The 3-21 + G basis set for first-row elements, lithium to fluorine. J. Comput. Chem. 1983, 4, 294-301.
24. Matthews, D. A.; Bolin, J. T.; Burridge, J. M.; Filman, D. J.; Volz, K. W.; Kraut, J. Dihydrofolate reductase. The stereochemistry of inhibitor selectivity. J. Biol. Chem. 1985, 260, 392-399.
25. Matthews, D. A.; Bolin, J. T.; Burridge, J. M.; Filman, D. J.; Volz, K. W.; Kaufman, B. T.; Beddell, C. R.; Champness, J. N.; Stammers, D. K.; Kraut, J. Refined crystal structures of Escherichia coli and chicken liver dihydrofolate reductase containing bound trimethoprim. J. Biol. Chem. 1985, 260, 381-391.
26. Roth, B.; Aig, E.; Lane, K.; Rauckman, B. S. 2,4-Diamino-5- benzylpyrimidines as antibacterial agents. 4. 6-Substituted trimethoprim derivatives from phenolic Mannich intermediates. Application to the synthesis of trimethoprim and 3,5-dialkylbenzyl analogues. J. Med. Chem. 1980, 23, 535-541.
27. Werbel, L. M. Design and synthesis of lipophilic antifols as anticancer agents. In Folate Antagonists as Therapeutic Agents. Volume I, Biochemistry, Molecular Actions and Synthetic Design; Sirotnak, F. M., Burchall, J. J., Ensminger, W. B., Montgomery, J. A., Eds.; Academic Press: New York, 1984; pp 261-287.
28. Baccanari, D. P.; Kuyper, L. F. Basis of selectivity of antibacterial diaminopyrimidines. J. Chemother. 1993, 5, 393-399.
29. Hartman, P. G. Molecular aspects and mechanism of action of dihydrofolate reductase inhibitors. J. Chemother. 1993, 5, 369-376.
30. Kisliuk, R. L.; Strumpf, D.; Gaumont, Y.; Leary, R. P.; Plante, L. Diastereoisomers of 5,10-methylene-5,6,7,8-tetrahydropteroyl-D-glutamic acid. J. Med. Chem. 1977, 20, 1531-1533.
31. Prendergast, N. J.; Delcamp, T. J.; Smith, P. L.; Freisheim, J. H. Expression and site-directed mutagenesis of human dihydrofolate reductase. Biochemistry 1988, 27, 3664-3671.
32. Broughton, M. C.; Queener, S. F. Pneumocystis carinii dihydrofolate reductase used to screen potential antipneumocystis drugs. Antimicrob. Agents Chemother. 1991, 35, 1348-1355.
33. Chio, L. C.; Queener, S. F. Identification of highly potent and selective inhibitors of Toxoplasma gondii dihydrofolate reductase. Antimicrob. Agents Chemother. 1993, 37, 1914-1923.
34. Zywno-van-Ginkel, S.; Dooley, T. P.; Suling, W. J.; Barrow, W. W. Identification and cloning of the Mycobacterium avium folA gene, required for dihydrofolate reductase activity. FEMS Microbiol. Lett. 1997, 156, 69-78.
35. Suling, W. J.; Reynolds, R. C.; Barrow, E. W.; Wilson, L. N.; Piper, J. R.; Barrow, W. W. Susceptibilities of Mycobacterium tuberculosis and Mycobacterium avium complex to lipophilic deazapteridine derivatives, inhibitors of dihydrofolate reductase. J. Antimicrob. Chemother. 1998, 42, 811-815.
36. Suling, W. J.; Seitz, L. E.; Pathak, V.; Westbrook, L.; Barrow, E. W.; Zywno-van-Ginkel, S.; Reynolds, R. C.; Piper, J. R.; Barrow, W. W. Antimycobacterial activities of 2,4-diamino-5-deazapteridine derivatives and effects on mycobacterial dihydrofolate reductase. Antimicrob. Agents Chemother. 2000, 44, 2784-2791.
37. Bakerman, H. A. A method for measuring the microbiological activity of tetrahydrofolic acid and other labile reduced folic acid derivatives. Anal. Biochem. 1961, 2, 558-567.
38. Reynolds, R. C.; Tiwari, A.; Harwell, J. E.; Gordon, D. G.; Garrett, B. D.; Gilbert, K. S.; Schmid, S. M.; Waud, W. R.; Struck, R. F. Synthesis and evaluation of several new (2-chloroethyl)nitrosocarbamates as potential anticancer agents. J. Med. Chem. 2000, 43, 1484-1488.
39. 7Li reaction. Med. Phys. 1986, 13, 50-56.